Paperpal Prime Logo

Molecular Therapy - Nucleic Acids : Impact Factor & More

eISSN: 2162-2531pISSN: 2162-2531
JournalOpen Access

Key Metrics

CiteScore
12.9
Eigenfactor
0.01 - 0.05
Impact Factor
5 - 10
SJR
Q1Drug Discovery
SNIP
1.42
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Molecular Therapy - Nucleic Acids

Molecular Therapy - Nucleic Acids Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher CELL PRESS
Language English
Frequency Quarterly
Article Processing ChargesUSD 3900
Publication Time20
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
Society/Institute/SponsorAmerican Society of Gene & Cell Therapy
FrequencyQuarterly
Publication Start Year2012
Publisher URLVisit website
Website URLVisit website
Publication Details
Publication Time 20
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC-ND
OA statementVisit website
View less

Planning to publish in Molecular Therapy - Nucleic Acids ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Molecular Therapy - Nucleic Acids

Pyroptosis as a novel therapeutic target in glioblastoma multiforme: Mechanisms, molecular insights, and therapeutic potential.
  • 8 Sep 2026
  • Molecular therapy. Nucleic acids
Targeted gene editing of PCCA pseudoexon using CRISPR-Cas12a for potential therapy in propionic acidemia.
  • 8 Sep 2026
  • Molecular therapy. Nucleic acids
Advances in ex vivo mRNA-based gene transfer for cell-based cancer immunotherapy.
  • 8 Sep 2026
  • Molecular therapy. Nucleic acids
A versatile VLP-mediated CRISPR-RNP platform for precise genome editing and durable epigenome silencing in cancer.
  • 8 Sep 2026
  • Molecular therapy. Nucleic acids
Decoding preeclampsia: A fusion of multi-view machine learning and multi-omics to identify putative inflammation-related mechanisms.
  • 8 Sep 2026
  • Molecular therapy. Nucleic acids
Understanding the biological limits of hybridization-dependent siRNA off-target interactions.
  • 8 Sep 2026
  • Molecular therapy. Nucleic acids
Pyroptosis as a novel therapeutic target in glioblastoma multiforme: Mechanisms, molecular insights, and therapeutic potential.
  • 8 Sep 2026
  • Molecular therapy. Nucleic acids
Targeted gene editing of PCCA pseudoexon using CRISPR-Cas12a for potential therapy in propionic acidemia.
  • 8 Sep 2026
  • Molecular therapy. Nucleic acids
Advances in ex vivo mRNA-based gene transfer for cell-based cancer immunotherapy.
  • 8 Sep 2026
  • Molecular therapy. Nucleic acids
A versatile VLP-mediated CRISPR-RNP platform for precise genome editing and durable epigenome silencing in cancer.
  • 8 Sep 2026
  • Molecular therapy. Nucleic acids
Decoding preeclampsia: A fusion of multi-view machine learning and multi-omics to identify putative inflammation-related mechanisms.
  • 8 Sep 2026
  • Molecular therapy. Nucleic acids
Understanding the biological limits of hybridization-dependent siRNA off-target interactions.
  • 8 Sep 2026
  • Molecular therapy. Nucleic acids

FAQs on Molecular Therapy - Nucleic Acids